Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

(2021) Lawrence Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS

(2021) Martina S. Wesley et al.   Frontiers in Immunology

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

(2021) Kathryn E. Stephenson et al.   NATURE MEDICINE

Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

(2020) Kathryn E. Stephenson et al.   Annual Review of Immunology

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Trevor A Crowell et al.   Lancet HIV

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

(2019) Christine A. Bricault et al.   Cell Host & Microbe

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

(2019) Kevin O. Saunders et al.   SCIENCE

HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure

(2018) Peter D. Kwong et al.   IMMUNITY

Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection

(2018) Hongshuo Song et al.   Nature Communications

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

(2018) Kshitij Wagh et al.   PLoS Pathogens

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

(2018) Yotam Bar-On et al.   NATURE MEDICINE

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

(2018) Erica N. Borducchi et al.   NATURE

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure

(2017) Jeong Hyun Lee et al.   IMMUNITY

Early antibody therapy can induce long-lasting immunity to SHIV

(2017) Yoshiaki Nishimura et al.   NATURE

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

(2017) Ling Xu et al.   SCIENCE

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

(2017) Boris Julg et al.   Science Translational Medicine

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

(2017) Boris Julg et al.   Science Translational Medicine

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

(2016) Jon M. Steichen et al.   IMMUNITY

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

(2016) Katharine J. Bar et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

(2016) T. Schoofs et al.   SCIENCE

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

(2016) C.-L. Lu et al.   SCIENCE

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

(2016) Kshitij Wagh et al.   PLoS Pathogens

Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis

(2016) Martin Hoenigl et al.   Scientific Reports

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

(2015) Nicole A. Doria-Rose et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

CATNAP: a tool to compile, analyze and tally neutralizing antibody panels

(2015) Hyejin Yoon et al.   NUCLEIC ACIDS RESEARCH

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

(2014) Devin Sok et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248

(2013) Adriana Andrade et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life

(2013) N L Yates et al.   Mucosal Immunology

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

(2013) Dan H. Barouch et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies

(2009) M. S. Seaman et al.   JOURNAL OF VIROLOGY

Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

(2008) G. D. Tomaras et al.   JOURNAL OF VIROLOGY

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA